Evidence map›Paper›PMID 40108236›Full record

ArticleScientific reports2025

Predicting coronavirus disease 2019 severity using explainable artificial intelligence techniques.

Takuya Ozawa, Shotaro Chubachi, Ho Namkoong, Shota Nemoto, Ryo Ikegami, Takanori Asakura, Hiromu Tanaka, Ho Lee, Takahiro Fukushima, Shuhei Azekawa and 30 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors.

Takuya Ozawa *Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Shotaro Chubachi *Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. bachibachi472000@z6.keio.jp.
Ho Namkoong *Department of Infectious Diseases, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. hounamugun@gmail.com.
Shota NemotoIndustrial and Digital Business Unit, Hitachi, Ltd, Tokyo, Japan.
Ryo IkegamiIndustrial and Digital Business Unit, Hitachi, Ltd, Tokyo, Japan.
Takanori AsakuraDivision of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Hiromu TanakaDivision of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Ho LeeDivision of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Takahiro FukushimaDivision of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Shuhei AzekawaDivision of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Shiro OtakeDivision of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Kensuke NakagawaraDivision of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Mayuko WataseDivision of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Katsunori MasakiDivision of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Hirofumi KamataDivision of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Norihiro HaradaDepartment of Respiratory Medicine, Faculty of Medicine, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Tetsuya UedaDepartment of Respiratory Medicine, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
Soichiro UedaJCHO (Japan Community Health Care Organization, Internal Medicine, Saitama Medical Center, Saitama, Japan.
Takashi IshiguroDepartment of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Saitama, Japan.
Ken ArimuraDepartment of Respiratory Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Fukuki SaitoDepartment of Emergency and Critical Care Medicine, Kansai Medical University General Medical Center, Osaka, Japan.
Takashi YoshiyamaRespiratory Disease Center, Fukujuji Hospital, Tokyo, Japan.
Yasushi NakanoDepartment of Internal Medicine, Kawasaki Municipal Ida Hospital, Kawasaki, Kanagawa, Japan.
Yoshikazu MutoDepartment of Infectious Diseases, Tosei General Hospital, Aichi, Japan.
Yusuke SuzukiDepartment of Clinical Medicine (Laboratory of Bioregulatory Medicine), Kitasato University School of Pharmacy, Tokyo, Japan.
Ryuya EdahiroDepartment of Statistical Genetics, Osaka University Graduate School of Medicine, Osaka, Japan.
Koji MurakamiDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Miyagi, Japan.
Yasunori SatoBiostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan.
Yukinori OkadaDepartment of Statistical Genetics, Osaka University Graduate School of Medicine, Osaka, Japan.
Ryuji KoikeHealth Science Research and Development Center, Tokyo Medical and Dental University, Tokyo, Japan.
Makoto IshiiDivision of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Naoki HasegawaDepartment of Infectious Diseases, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Yuko KitagawaDepartment of Surgery, Keio University School of Medicine, Tokyo, Japan.
Katsushi TokunagaGenome Medical Science Project (Toyama), National Center for Global Health and Medicine, Tokyo, Japan.
Akinori KimuraInstitute of Research, Tokyo Medical and Dental University, Tokyo, Japan.
Satoru MiyanoM&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan.
Seishi OgawaDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.
Takanori KanaiDivision of Gastroenterology and Hepatology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Koichi FukunagaDivision of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Seiya Imoto *Division of Health Medical Intelligence, Human Genome Center, the Institute of Medical Science, the University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-0071, Japan. imoto@hgc.jp.

Funding

Japan Agency for Medical Research and Development JP20fk0108452Japan Agency for Medical Research and Development JP20nk0101612Japan Agency for Medical Research and Development JP21fk0108563Japan Agency for Medical Research and Development JP21jk0210034Japan Agency for Medical Research and Development JP21km0405211Japan Agency for Medical Research and Development JP22wm0325031Japan Science and Technology Agency JPMJCR20H2Japan Science and Technology Agency JPMJPR21R7Ministry of Health, Labour and Welfare 20CA2054
6 · The paper itself

Abstract

Predictive models for determining coronavirus disease 2019 (COVID-19) severity have been established; however, the complexity of the interactions among factors limits the use of conventional statistical methods. This study aimed to establish a simple and accurate predictive model for COVID-19 severity using an explainable machine learning approach. A total of 3,301 patients ≥ 18 years diagnosed with COVID-19 between February 2020 and October 2022 were included. The discovery cohort comprised patients whose disease onset fell before October 1, 2020 (N = 1,023), and the validation cohort comprised the remaining patients (N = 2,278). Pointwise linear and logistic regression models were used to extract 41 features. Reinforcement learning was used to generate a simple model with high predictive accuracy. The primary evaluation was the area under the receiver operating characteristic curve (AUC). The predictive model achieved an AUC of ≥ 0.905 using four features: serum albumin levels, lactate dehydrogenase levels, age, and neutrophil count. The highest AUC value was 0.906 (sensitivity, 0.842; specificity, 0.811) in the discovery cohort and 0.861 (sensitivity, 0.804; specificity, 0.675) in the validation cohort. Simple and well-structured predictive models were established, which may aid in patient management and the selection of therapeutic interventions.

Indexed as

Artificial IntelligenceCOVID-19AdultAgedArea Under CurveFemaleHumansLogistic ModelsMachine LearningMaleMiddle AgedROC CurveSARS-CoV-2Severity of Illness IndexArtificial intelligenceCOVID-19Machine learning

Identifiers

PMID40108236
PMCPMC11923144

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.